Liver Injury Diagnosis and Management
Definition and Classification
- The American Association for the Study of Liver Diseases defines liver injury elevation as follows: mild (ALT/AST <3× ULN), moderate (ALT/AST 3-5× ULN), severe (ALT/AST >5× ULN), and life-threatening (ALT/AST >20× ULN) 1
Drug-Induced Liver Injury
- For suspected drug-induced liver injury, a detailed medication history is recommended, and discontinuation of the suspected medication is advised, with weekly monitoring of liver tests initially 1, 2
Viral Hepatitis
- HBV patients receiving immunosuppressive therapy should receive antiviral prophylaxis to prevent HBV reactivation, as recommended by guidelines 3
Laboratory Testing and Assessment
- Initial laboratory testing should include a complete liver panel, hepatitis serology, metabolic panel, and consideration of autoimmune markers if suspected, as recommended by the American Autoimmune Related Diseases Association, the European Association for the Study of the Liver, and the American Gastroenterological Association 4, 5, 6, 7
A standard hepatic function panel should include:
Test Description Albumin Marker of synthetic function Prothrombin Time (PT)/International Normalized Ratio (INR) Assesses blood clotting function Bilirubin (Total and Direct/Conjugated) Elevated in various liver and biliary conditions Complete Blood Count (CBC) Important for platelet count Aminotransferases (ALT/AST) Typically elevated in liver injury, with ALT being more liver-specific [6, 1, 4] The AST:ALT ratio can help differentiate between alcoholic liver disease, advanced fibrosis/cirrhosis, and viral hepatitis, with the following conditions having variable AST:ALT ratios:
Condition AST:ALT Ratio Alcoholic Liver Disease >2 Wilson Disease variable Glycogen Storage Disease Type III variable Imaging and Referral
- Abdominal ultrasound is recommended to evaluate liver architecture and rule out biliary obstruction, as suggested by the Mayo Clinic Proceedings 11
- Referral to a hepatologist should not be delayed for patients with signs of liver failure or persistent unexplained elevations, as suggested by the American Gastroenterological Association and the European Association for the Study of the Liver 7, 2
Management and Monitoring
- Discontinuation of potential hepatotoxic medications is crucial, with serial monitoring of liver tests, as recommended by the Alimentary Pharmacology and Therapeutics and the American Association for the Study of Liver Diseases (AASLD) 1, 11
- Patients with mild, asymptomatic elevations should have repeat testing in 2-4 weeks, while those with moderate elevations should have repeat testing in 1-2 weeks, and those with severe elevations should be monitored every 1-3 days until improving, as recommended by the American Gastroenterological Association and the American Autoimmune Related Diseases Association 7, 4
- The American Association for the Study of Liver Diseases recommends calculating FIB-4 or NAFLD fibrosis score to assess risk of advanced fibrosis, and considering non-invasive assessment of fibrosis, such as transient elastography (FibroScan) or Enhanced Liver Fibrosis (ELF) test, if available 12
Diagnosis of MASLD
- Premature attribution to MASLD is a common pitfall, as MASLD is a diagnosis of exclusion after ruling out other causes, as noted by the Mayo Clinic Proceedings 11
- The American Association for the Study of Liver Diseases recommends evaluating for MASLD as the likely cause in patients with persistently elevated ALT and AST over several years, with close monitoring and lifestyle modifications as first-line management 12
- A hepatocellular injury pattern (predominant transaminase elevation) rather than cholestatic, with an AST:ALT ratio of approximately 1:1, is consistent with non-alcoholic causes, as suggested by the European Association for the Study of the Liver 12